Charles Schwab Investment Management Inc Biotechnology

Charles Schwab Investment Management Inc

$521 Billion
Q1 2025

Stock List

Stock	Market Cap.	Holding Value (Reported)	# of Shares.	Last Trade	Trade History
FHTX Foghorn Therapeutics Inc.	$258M	$275,000 0.0% of portfolio	75,495	Q3 2024 Added 10.22%
ADCT Adc Therapeutics Sa	$251M	$273,000 0.0% of portfolio	194,258	Q3 2024 Added 10.71%
NKTX Nkarta, Inc.	$104M	$271,000 0.0% of portfolio	147,551	Q1 2025 Added 18.03%
LCTX Lineage Cell Therapeutics, Inc.	$195M	$226,000 0.0% of portfolio	503,193	Q1 2025 Added 20.9%
CABA Cabaletta Bio, Inc.	$47.6M	$222,000 0.0% of portfolio	159,866	Q1 2025 Added 46.32%
XBIT X Biotech Inc.	$88.6M	$218,000 0.0% of portfolio	67,355	Q1 2025 Added 15.26%
LRMR Larimar Therapeutics, Inc.	$149M	$215,000 0.0% of portfolio	100,457	Q1 2025 Reduced 19.72%
RAPT Rapt Therapeutics, Inc.	$375M	$184,000 0.0% of portfolio	150,946	Q1 2025 Added 112.66%
VERU Veru Inc.	$48.1M	$183,000 0.0% of portfolio	375,291	Q1 2025 Added 20.97%
GLSI Greenwich Life Sciences, Inc.	$144M	$181,000 0.0% of portfolio	19,007	Q1 2025 Added 15.51%
ETON Eton Pharmaceuticals, Inc.	$380M	$171,000 0.0% of portfolio	13,247	Q1 2025 Added 0.06%
BDTX Black Diamond Therapeutics, Inc.	$109M	$169,000 0.0% of portfolio	109,224	Q3 2024 Added 6.87%
ATNM Actinium Pharmaceuticals, Inc.	$46.8M	$157,000 0.0% of portfolio	97,604	Q1 2025 Added 35.39%
TCRX T Scan Therapeutics, Inc.	$35.6M	$155,000 0.0% of portfolio	112,941	Q2 2024 Added 410.95%
IGMS Igm Biosciences, Inc.	$37.1M	$144,000 0.0% of portfolio	125,614	Q1 2025 Reduced 20.42%
GBIO Generation Bio Co.	$248M	$142,000 0.0% of portfolio	356,441	Q1 2025 Reduced 2.88%
ALXO Alx Oncology Holdings Inc	$22M	$130,000 0.0% of portfolio	211,051	Q1 2025 Reduced 2.61%
STRO Sutro Biopharma, Inc.	$48M	$129,000 0.0% of portfolio	199,901	Q1 2025 Reduced 20.67%
IPSC Century Therapeutics, Inc.	$38.9M	$129,000 0.0% of portfolio	270,820	Q1 2025 Reduced 24.31%
ABOS Acumen Pharmaceuticals, Inc.	$65.2M	$128,000 0.0% of portfolio	116,902	Q1 2025 Reduced 7.77%
ABEO Abeona Therapeutics Inc.	$39.3M	$116,000 0.0% of portfolio	24,457	Q1 2025 Added 2.55%
XFOR X4 Pharmaceuticals, Inc	$102M	$115,000 0.0% of portfolio	481,528	Q1 2025 Added 9.89%
PYXS Pyxis Oncology, Inc.	$43.9M	$112,000 0.0% of portfolio	115,237	Q1 2025 Reduced 11.19%
INZY Inozyme Pharma, Inc.	$161M	$111,000 0.0% of portfolio	122,290	Q1 2025 Reduced 14.58%
HLVX Hille Vax, Inc.	$69.9M	$110,000 0.0% of portfolio	75,937	Q1 2025 Added 0.45%
STTK Shattuck Labs, Inc.	$36.9M	$108,000 0.0% of portfolio	114,139	Q3 2024 Reduced 5.64%
MNOV Medicinova Inc	$66.2M	$104,000 0.0% of portfolio	71,506	Q3 2024 Reduced 46.95%
ELDN Eledon Pharmaceuticals, Inc.	$51M	$101,000 0.0% of portfolio	29,987	Q4 2024 Added 100.09%
NAUT Nautilus Biotechnology, Inc.	$94.7M	$99,000 0.0% of portfolio	115,418	Q1 2025 Added 0.16%
CRVS Corvus Pharmaceuticals, Inc.	$214M	$95,000 0.0% of portfolio	29,968	Q4 2024 Added 91.27%
MRSN Mersana Therapeutics, Inc.	$31.1M	$95,000 0.0% of portfolio	280,631	Q1 2025 Reduced 10.23%
HOWL Werewolf Therapeutics, Inc.	$40.5M	$92,000 0.0% of portfolio	95,712	Q1 2025 Added 33.19%
PRLD Prelude Therapeutics Inc	$33.1M	$87,000 0.0% of portfolio	114,050	Q1 2025 Reduced 2.69%
TNYA Tenaya Therapeutics, Inc.	$36M	$74,000 0.0% of portfolio	130,192	Q1 2025 Reduced 14.68%
LIFE A Tyr Pharma Inc	$53.2M	$74,000 0.0% of portfolio	39,911	Q1 2025 Added 0.56%
AVTE Aerovate Therapeutics, Inc.	$65.5M	$73,000 0.0% of portfolio	29,351	Q3 2024 Reduced 43.65%
RZLT Rezolute, Inc.	$243M	$65,000 0.0% of portfolio	22,757	Q4 2024 Added 65.42%
TARA Protara Therapeutics, Inc.	$37.5M	$63,000 0.0% of portfolio	15,000	Q1 2025 New
VXRT Vaxart, Inc.	$51.9M	$62,000 0.0% of portfolio	153,547	Q3 2024 Reduced 0.03%
PEPG Pep Gen Inc.	$33.1M	$56,000 0.0% of portfolio	40,070	Q1 2025 Reduced 17.13%
DMAC Dia Medica Therapeutics Inc.	$130M	$50,000 0.0% of portfolio	13,253	Q1 2025 Added 0.02%
RNXT Renovo Rx, Inc.	$11.5M	$48,000 0.0% of portfolio	49,232	Q3 2023 New
ELEV Elevation Oncology, Inc.	$8.85M	$47,000 0.0% of portfolio	181,694	Q1 2025 Added 46.31%
OVID Ovid Therapeutics Inc.	$47.2M	$42,000 0.0% of portfolio	135,487	Q1 2025 Reduced 16.27%
ANIX Anixa Biosciences Inc	$101M	$36,000 0.0% of portfolio	12,785	Q3 2022 Reduced 47.2%
SEER Seer, Inc.	$128M	$30,000 0.0% of portfolio	18,105	Q1 2025 Added 1.33%
GALT Galectin Therapeutics Inc	$171M	$27,000 0.0% of portfolio	22,913	Q1 2025 Reduced 64.79%
IMUX Immunic, Inc.	$32.4M	$27,000 0.0% of portfolio	25,000	Q3 2024 Reduced 0.4%
DYAI Dyadic International Inc	$30.7M	$22,000 0.0% of portfolio	16,336	Q2 2023 New
ACET Adicet Bio, Inc.	$31.2M	$22,000 0.0% of portfolio	30,000	Q4 2024 Reduced 0.13%

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.